205 related articles for article (PubMed ID: 32886753)
1. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Robak T; Kaźmierczak M; Jarque I; Musteata V; Treliński J; Cooper N; Kiessling P; Massow U; Woltering F; Snipes R; Ke J; Langdon G; Bussel JB; Jolles S
Blood Adv; 2020 Sep; 4(17):4136-4146. PubMed ID: 32886753
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Newland AC; Sánchez-González B; Rejtő L; Egyed M; Romanyuk N; Godar M; Verschueren K; Gandini D; Ulrichts P; Beauchamp J; Dreier T; Ward ES; Michel M; Liebman HA; de Haard H; Leupin N; Kuter DJ
Am J Hematol; 2020 Feb; 95(2):178-187. PubMed ID: 31821591
[TBL] [Abstract][Full Text] [Related]
4. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.
Kiessling P; Lledo-Garcia R; Watanabe S; Langdon G; Tran D; Bari M; Christodoulou L; Jones E; Price G; Smith B; Brennan F; White I; Jolles S
Sci Transl Med; 2017 Nov; 9(414):. PubMed ID: 29093180
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM; McDonald V; Miyakawa Y; Carpenedo M; Kuter DJ; Al-Samkari H; Bussel JB; Godar M; Ayguasanosa J; De Beuf K; Rodeghiero F; Michel M; Newland A;
Lancet; 2023 Nov; 402(10413):1648-1659. PubMed ID: 37778358
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
8. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
[TBL] [Abstract][Full Text] [Related]
9. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL
N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891
[TBL] [Abstract][Full Text] [Related]
10. Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.
Liebman HA; Saleh MN; Bussel JB; Negrea OG; Horne H; Wegener WA; Goldenberg DM
Br J Haematol; 2013 Sep; 162(5):693-701. PubMed ID: 23829485
[TBL] [Abstract][Full Text] [Related]
11. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
Sun L; Wang J; Shao L; Yuan C; Zhao H; Li D; Wang Z; Han P; Yu Y; Xu M; Zhao H; Qiu J; Zhou H; Liu X; Hou Y; Peng J; Hou M
Lancet Haematol; 2021 Apr; 8(4):e289-e298. PubMed ID: 33770484
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells
Qureshi OS; Sutton EJ; Bithell RF; West SM; Cutler RM; McCluskey G; Craggs G; Maroof A; Barnes NM; Humphreys DP; Rapecki S; Smith BJ; Shock A
MAbs; 2024; 16(1):2300155. PubMed ID: 38241085
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Kuter DJ; Mayer J; Efraim M; Bogdanov LH; Baker R; Kaplan Z; Garg M; Trněný M; Choi PY; Jansen AJG; McDonald V; Bird R; Gumulec J; Kostal M; Gernsheimer T; Ghanima W; Daak A; Cooper N
Blood Adv; 2024 Apr; 8(7):1715-1724. PubMed ID: 38386978
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
16. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
[TBL] [Abstract][Full Text] [Related]
17. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia.
Broome CM; Röth A; Kuter DJ; Scully M; Smith R; Wang J; Reuter C; Hobbs W; Daak A
Blood Adv; 2023 Mar; 7(6):987-996. PubMed ID: 35973190
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).
Hong J; Bang SM; Mun YC; Yhim HY; Lee J; Lim HS; Oh D;
J Korean Med Sci; 2018 May; 33(19):e142. PubMed ID: 29736158
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
Kuter DJ; Bussel JB; Newland A; Baker RI; Lyons RM; Wasser J; Viallard JF; Macik G; Rummel M; Nie K; Jun S
Br J Haematol; 2013 May; 161(3):411-23. PubMed ID: 23432528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]